June 13th 2025
Both oral and subcutaneous formulations of the long-acting GLP-1 and amylin receptor agonist move into stage 3 clinical trials following positive feedback from regulators.
What's to Blame for Variable Home BP in Patients With Diabetes?
March 7th 2014Here: factors that can affect home BP readings . . .when to start antiretroviral therapy . . . coping strategies for the challenges of aging . . . triggers to avoid in hyperthyroid patients . . . insights into causes of childhood obesity.